Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Advances in Vaccines for Substance Use Disorders
share announcement

Advances in Vaccines for Substance Use Disorders

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biologics and Biosimilars".

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 1544

Special Issue Editor

Dr. Colin N. Haile

E-Mail Website
Guest Editor
Department of Psychology & TIMES, University of Houston, Houston, TX 77204, USA
Interests: neuroscience; behavioral pharmacology; medication development; vaccines; immunology

Special Issue Information

Dear Colleagues,

Immunotherapeutic vaccines that target substances associated with use disorders in humans may represent a novel treatment strategy. The indicated treatments for opioid and nicotine use disorders are plagued by non-compliance and low efficacy, and currently, no treatments are approved for cocaine and methamphetamine use disorders. Vaccines for these and other substance use disorders trigger an immune response, generating antibodies against a specific drug.  The antibodies bind to the targeted substance and prevent it from entering the brain, sequestering it in systemic circulation. Eventually, the substance is eliminated from the body and produces no psychoactive effects.  The scope of this Special Issue includes vaccines, adjuvants, screening methods and evaluations of these formulations in different stages of development with the utilization of in vitro and in vivo models. The development of efficacious vaccines has the potential to provide much-needed therapeutic options for the treatment of substance use disorders. 

Dr. Colin N. Haile
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccines
  • substance use disorder
  • immunotherapy
  • adjuvant
  • hapten
  • immunogenicity
  • antibody

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

17 pages, 674 KiB  
Review
Vaccines to Treat Substance Use Disorders: Current Status and Future Directions
by Tangsheng Lu, Xue Li, Wei Zheng, Chenyan Kuang, Bingyi Wu, Xiaoxing Liu, Yanxue Xue, Jie Shi, Lin Lu and Ying Han
Pharmaceutics 2024, 16(1), 84; https://doi.org/10.3390/pharmaceutics16010084 - 08 Jan 2024
Viewed by 1388
Abstract
Addiction, particularly in relation to psychostimulants and opioids, persists as a global health crisis with profound social and economic ramifications. Traditional interventions, including medications and behavioral therapies, often encounter limited success due to the chronic and relapsing nature of addictive disorders. Consequently, there [...] Read more.
Addiction, particularly in relation to psychostimulants and opioids, persists as a global health crisis with profound social and economic ramifications. Traditional interventions, including medications and behavioral therapies, often encounter limited success due to the chronic and relapsing nature of addictive disorders. Consequently, there is significant interest in the development of innovative therapeutics to counteract the effects of abused substances. In recent years, vaccines have emerged as a novel and promising strategy to tackle addiction. Anti-drug vaccines are designed to stimulate the immune system to produce antibodies that bind to addictive compounds, such as nicotine, cocaine, morphine, methamphetamine, and heroin. These antibodies effectively neutralize the target molecules, preventing them from reaching the brain and eliciting their rewarding effects. By obstructing the rewarding sensations associated with substance use, vaccines aim to reduce cravings and the motivation to engage in drug use. Although anti-drug vaccines hold significant potential, challenges remain in their development and implementation. The reversibility of vaccination and the potential for combining vaccines with other addiction treatments offer promise for improving addiction outcomes. This review provides an overview of anti-drug vaccines, their mechanisms of action, and their potential impact on treatment for substance use disorders. Furthermore, this review summarizes recent advancements in vaccine development for each specific drug, offering insights for the development of more effective and personalized treatments capable of addressing the distinct challenges posed by various abused substances. Full article
(This article belongs to the Special Issue Advances in Vaccines for Substance Use Disorders)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop